Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 96.1%

Neg 96.1% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.